Видео

thank u soooo much

the side effects will kill the patient! I would NEVER agree to this type of treatment!

Are there any studies using Metabolic Therapy for CML or AML? I started #Carnivore and my mutation load is going DOWN?

Who benefits adjuvant chemotherapy (ACT) in Stage 2 colon cancer? The updated DYNAMIC trial showed that patients with (-)ctDNA do not need ACT. meetings.asco.org/abstracts-presentations/234913

Treatment with sacituzumab tirumotecan significantly improved progression-free survival (PFS) and overall survival (OS) when compared to chemotherapy for patients with heavily pretreated, advanced triple-negative breast cancer, according to phase 3 data presented at the 2024 ASCO Annual Meeting. The antibody-drug conjugate sacituzumab tirumotecan targets TROP2, which is overexpressed in triple-negative breast cancer and often correlates with adverse outcomes. In a phase 3 study, researchers assigned 263 patients with advanced triple-negative breast cancer to monotherapy with sacituzumab tirumotecan (n = 130) or to physician’s choice chemotherapy (n = 133). The median age of the study cohort was 51 years, and the heavily pretreated population had received two or more previous therapies, including at least one therapy in the metastatic setting. In total, prior PD-1/PD-L1 inhibitors receipt was 26%, and 48% had received three or more lines of prior chemotherapy in the advanced setting. The rate of visceral metastases was 87%. PFS served as the primary endpoint. Results of an interim analysis revealed that assignment to sacituzumab tirumotecan correlated with a 69% reduction in the risk of progression or death (hazard ratio [HR] = 0.31; 95% CI, 0.22-0.45; P < .00001). The median PFS for patients assigned to sacituzumab tirumotecan was 5.7 months (95% CI, 4.3-7.2), compared to 2.3 months (95% CI, 1.6-2.7) for patients assigned to chemotherapy. The 6-month PFS rates were 43.4% and 11.1%, respectively. Among patients with a TROP2 H-score above 200, the median PFS with sacituzumab tirumotecan was 5.8 months, compared to 1.9 months for chemotherapy (HR = 0.28; 95% CI, 0.17-0.48). Median follow-up for OS was 10.4 months. The researchers observed a significant trend toward improved OS for patients assigned to sacituzumab tirumotecan (median, not reached vs 9.4 months; HR = 0.53; 95% CI, 0.36-0.78; P = .0005). The objective response rate also favored sacituzumab tirumotecan (43.8% vs 12.8%). Treatment with sacituzumab tirumotecan was well tolerated. The most common treatment-related adverse events (grade 3 or higher) included decreased neutrophil count (sacituzumab tirumotecan vs chemotherapy, 32.3% vs 47%), anemia (27.7% vs 6.1%), and decreased white blood cell count (25.4% vs 36.4%).

FDA approved repotrektinib for metastatic solid tumor with NYRK fusion. www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive#:~:text=On%20June%2013%2C%202024%2C%20the,advanced%20or%20metastatic%20or%20where

FDA approved fam-trastuzumab deruxican (Enhertu) for any solid tumor with HER2 (+). www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

FDA approved BRAF inhibitor for all solid cancer with BRAFV600E mutation. www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid

www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-ret-fusion-positive-thyroid-cancer#:~:text=On%20June%2012%2C%202024%2C%20the,and%20who%20are%20radioactive%20iodine%2D

FDA approved Selpercatinib for RET rearrangement thyroid cancer. About 20% papillary and 65% medullary thyroid cancer express RET. express RET.

Adagrasib was approved by FDA for metastatic colorectal cancer with KRAS G12C mutation. It is combined with cetuximab with 35% responses rate: www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer

Brahmi Chyawanprash for planet ayurveda It supports almost all systems of the body. It is a purely natural product and does not contain binders, preservatives, additives, yeast, and fillers in it.

Thank you immune Booster for Planet Ayurveda is a very good product for itp patient

교수님, 안녕하세요? 질문이 있어 댓글 남깁니다. 몇 년 전 유방암 1기로 방사선 치료만 했었고, 올해 유방 원발 미만성거대B세포림프종-ABC 1기 진단 받은 환우 보호자입니다. (환우 나이 만 57세) 알찹 6회+MTX 2회 진행하였고 3차 항암 후 중간검사 결과도 매우 좋았고, 항암 마친 후 최종검사했을 때 혈액은 완전 깨끗해졌다고 했습니다. 그런데 CT에는 안 보이는데 PET에서 오른쪽 난소에 뭔가 움직임이 보인다고, 이게 생리 현상인지 병인지를 모르겠으니 3개월 뒤 추적검사 때 PET를 다시 찍어보자고 하십니다. 1. 폐경 후에 난소 움직임이 보이는 게 혹시 종양 전이일 수 있는지 아니면 다른 가능성도 있을 수 있는지 궁금합니다. 전이성 종양 가능성이 있다면 3개월 기다렸다가 검사하지 않고 산부인과에서 초음파든 다른 검사든 해보는 게 나은 건 아닐까요? 왜 3개월 뒤에 추적검사 때 PET를 다시 찍어서 확인하자고 하신 걸까요? 걱정이 많이 됩니다…. 2. 유방 원발이라 뇌, 중추신경 전이 가능성이 높으니 예방적으로 MTX 3회를 하자고 하셨다가 2회만 하고 마무리하였습니다. 주치의인 교수님께서는 논문에서 MTX가 실질적인 효과가 있는지는 입증되지 않았고 전통적으로 그렇게 해왔기에 예방항암을 하는 거라서 큰 문제 없다고 하셨는데, 공격성 아형이라 더 적극적으로 해야 하는 거 아닌가 싶은데 교수님께서는 이에 대해 어떻게 보시나요? 3. 고용량 비타민C 정맥주사의 효과에 대한 논문을 보면 결론이 정반대인데 항암 종료 후에 정기적으로 맞는 거에 대해 교수님은 어떻게 생각하시는지 궁금합니다.

The only barriers to curing diseases, are lack of knowledge, skill and experience of the scientists, doctors and specialists in these fields of disease. We're interested in the curing.

I read that constantly high transferrin saturation levels can cause organ damage despite normal ferritin levels. Is this true?

Planet Ayurveda has the best ITP treatment. My platelet count has improved, and I feel great.

Imetelstat: New drug for EPO refractory MDS was approved by FDA. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imetelstat-low-intermediate-1-risk-myelodysplastic-syndromes-transfusion-dependent

We're are you located and phone numbers and address

What about THIO-101? Targeting Telomeres to Clear Cancer - Short vs Long Telomerase | Aubrey De Grey

Dr Kim… if stage 1b TNBC / lesion 8mmx4mm found ~ in rt breast ~ on routine mammogram ~ had neoadjunctice TC CHEMO prior to double Mastectomy ( profilactic ) NEG Sentinal nodes and Lymph nodes on surgical pathology report… no suspicious nodes found prior to treatment with complete tumor response to chemo….QUESTION: Sentinal Node and Lymph node biopsy ( blue dye) was done ONLY after neoadjunctive chemo… could micro seedlings of cancer cells in nodes even have been determined in said nodes if they were already dead from prior chemo therapy ⁉️⁉️ ⁉️⁉️⁉️ neoadjuctive therapy; would microseedlings to

Thank you for sharing. 5th year

The US Food and Drug Administration has granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab is a first-in-class bispecific T-cell engager (BiTE) that binds delta-like ligand 3 on the surface of cells, including tumor cells, and CD3 expressed on the surface of T-cells. It causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells, according to labeling. Approval was based on data from 99 patients in DeLLphi-301 trial with relapsed/refractory extensive-stage SCLC who had progressed after platinum-based chemotherapy Patients with symptomatic brain metastases, interstitial lung disease, noninfectious pneumonitis, and active immunodeficiency were excluded. The overall response rate was 40%, and median duration of response 9.7 months. The overall response rate was 52% in 27 patients with platinum-resistant SCLC and 31% in 42 with platinum-sensitive disease. Continued approval may depend on verification of clinical benefit in a confirmatory trial. Labeling includes a box warning of serious or life-threatening cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome. The most common adverse events, occurring in 20% or more of patients, were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. The most common grade 3 or 4 laboratory abnormalities included decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium. The starting dose is 1 mg given intravenously over 1 hour on the first day of the first cycle followed by 10 mg on day 8 and day 15 of the first cycle, then every 2 weeks until disease progression or unacceptable toxicity.

Thank you so much Dr kim! ❤️❤️❤️

Dr is there any merit to Dr Thomas Seyfried approach to starving cancer by depriving it of glucose and glutamine.

Is immunotherapy doable in case of Hodgkin lymphoma ?

Thank you Doctor

감사합니다. 남편이 Vrd로 치료시작했습니다. D-vdt 로 할줄알았는데 Vrd로 하신다네요. 어떤 차이점이 있을까요?

I am heterozygous for H63D, my entire family on my mother's line has hemochromatosis, so in some way we inherit it dominantly. I was diagnosed at 38 years old, with 1200 ferritin and a saturation of 50%, 90umol/g of iron in the liver.

Thank you sir your lecture helped understand the process of investigation

Thank you for your time to produce this video Dr. Kim. I am on Pembro for a year for 911 related throat cancer. I am being treated at Sloan Kettering. I had a laryngectomy. This is my second bout with the squamous cell carcinoma. The only reaction I had was the rash and itching. Again thank you Dr. Kim.

New bispecific T cell Engager (BiTE) for SCLC In May 2024, the FDA has granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab is a first-in-class bispecific T-cell engager (BiTE) that binds delta-like ligand 3 on the surface of cells, including tumor cells, and CD3 expressed on the surface of T-cells. It causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Approval was based on data from 99 patients in DeLLphi-301 trial with relapsed/refractory extensive-stage SCLC who had progressed after platinum-based chemotherapy Patients with symptomatic brain metastases, interstitial lung disease, noninfectious pneumonitis, and active immunodeficiency were excluded. The overall response rate was 40%, and median duration of response 9.7 months. The overall response rate was 52% in 27 patients with platinum-resistant SCLC and 31% in 42 with platinum-sensitive disease. Continued approval may depend on verification of clinical benefit in a confirmatory trial. Labeling includes a box warning of serious or life-threatening cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome. The most common adverse events, occurring in 20% or more of patients, were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. The most common grade 3 or 4 laboratory abnormalities included decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium. The starting dose is 1 mg given intravenously over 1 hour on the first day of the first cycle followed by 10 mg on day 8 and day 15 of the first cycle, then every 2 weeks until disease progression or unacceptable toxicity.

Thank you for your video and for the Psalm at the end. God Bless!

My red blood cells count is 5.13 is that normal?

Show me the data on super saturation… I want to see your data on 1,000+mg doses. ER+ BC can usually be knocked out in less than 6mo using 2,000mg CBD and 1,000mg RSO per day. Similar to bone cancers and brain cancers.

PS per Cristina Sanchez… THC kills every single cancer type in a dose dependent manor. The exception is certain brain tumors that are in the midbrain like DIPG. There is not one cancer that is made worse by Cannabinoids, that has been confirmed also by scientists at HU. Hahaha this doctor is using wayyyy too many old and political studies. 2019 or newer. Sativex and Epidiolex are garbage medicines.

I have met and watched multiple people use Cannabinoids only and walk away cancer free. My success rate is currently 100% on cancers, with 4 people currently using proper dosages. Matter of time before their results become available. The problem is these doctors want to ignore the fact that there is no overdose, it is a dose dependent treatment. I have seen pancreatic cancer patients need 3,000mgs of RSO per day while most need far less. It also isn’t just THC either, almost all known Cannabinoids have anti-cancer properties. It is always best to use large doses of both. As for cardio effects, the act of smoking is dangerous no matter which drug you choose. This is how people damage their endothelial cells with Cannabis. People should be ingesting, taking sublingually, transdermally or via suppository. This video doesn’t even scratch the surface of Cannabinoid medicine. Hahahaha this dr obviously has a lot of money invested in big pharma, half of these stats have been proven incorrect. I’ve read almost every study he is talking about, the data is crap. And most of these scary sounding side effects are minor and temporary, often times not even seen. Hahaha haha gateway drug? That isn’t what state wide studies show on Opioid use after Cannabis legalization… every single time. Hahaha hahaha I take anywhere between 500-1,000mgs of THC per day… everyone of my biomarkers that were in the red… went into the green. My blood pressure is also down. Hahaha after my second Cauda Equina Surgery, I was up to 7,000mg of THC per day for a few weeks, dropped down to 3,000mg once the pain calmed down…. Took multiple breaks with the only withdrawal symptom being 1 or 2 days struggling to fall asleep. Nada. Plus we know how to treat CHS, which is about the only actual direct danger associated with Cannabis use.

In November 2023, the FDA approved pembrolizumab + chemo (FP or CAPOX) for advanced/metastatic HER2(-) gastric or GEJ adenocarcinoma. When compared with chemo + placebo, improved OS (12.9 vs. 11.5 mon) and ORR 51 vs42%. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction

14프로 이상의 다발 골수종 환자가 20년 이상 장기생존 하신다고 하셨는데. 전부 항암치료 후 그렇게 지내시는건 가요? 아니면 치료 하지 않고 그냥 내버려둬도 그렇게 돤다는 말씀 이신가요??

How to prevent from Immune Thrombocytopenia forever click the link below 👇 ruclips.net/video/yOTC_IPbrn4/видео.htmlsi=0laN6vlLBLKUtEpk

Hello doc I have polycythemia it's now 3 years how can I contact you,thank you in advance.

Thank you Dr.

New published report showed cannabis law for recreational use didn’t affect the use of opioids and opioid use related mortality. jamanetwork.com/journals/jama-health-forum/fullarticle/2813866

👍 very well explained

Why no mention of Keytruda for right side colon cancer?

Is NSCLC squamous cell HPV+ second primary tumor in both lungs and mediastinum curable ?

you said i had lymph nodes infected in lower back. shows up on test i took.could it b bladder cancer? listen to doctors talk about finding and treating it. there’s bladder testing,blood tests and lymph nodes testing removing bladder and replacing with another item. with immunotherapies they have 70%sucess rate or more. just listen to this pop cast.

I wish my state had “Dying with Dignity” legislation passed.

IF YOU HAVE CANCER CK OUT JOE TIPPENS CANCER PROTOCOL FENBENDAZOLE RIGHT AWAY, FENBENDAZOLE REDUCES AND KILLS CANCER CELLS WITH OUT ANY SIDE EFFECTS. AND CAN BE USED AS A PROPHYLACTIC AGAINST CANCER. NOT HARD TO USE, WHAT HAVE YOU GOT TO LOSE. JESUS LOVES YOU ❤❤❤

This is great